{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:30:48Z","timestamp":1780327848796,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PhD studentship from the Higher Committee for Education Development (HCED) in Iraq"},{"name":"Ernest and Helen Scott Haematology Research Institute"},{"name":"Leicester Haematology Research Fund"},{"name":"Ernest and Helen Scott Haematology Research Institute Leicester Haematology Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with peripheral T-cell lymphomas generally have poor clinical outcomes with conventional chemotherapy. Recent advances have demonstrated that a large subgroup of PTCL are derived from follicular helper (Tfh) T-cells. These cases show a characteristic pattern of gene expression, which includes high-level protein expression of interleukin-2-inducible kinase (ITK). ITK is a member of the TEC family of kinases and normally has essential functions in regulating T-cell receptor signalling and T-cell differentiation. Here we report a side-by-side comparison of four ITK inhibitors. We investigate effects on apoptosis, phosphorylation of signaling molecules, calcium flux and migration. In line with a specific mechanism of action ONO7790500 and BMS509744 did not inhibit MEK1\/2 or AKT phosphorylation although other ITK inhibitors, ibrutinib and PF-06465469, did have this effect. Specific ITKi had modest effects on apoptosis alone but there was definite synergy with doxorubicin, pictilisib (PI3Ki) and idelalisib (PI3K\u03b4i). ITKi repressed migration of Jurkat cells caused by CXCL12 and the CXCR4 antagonist, plerixafor enhanced this effect. Overall ITKi may have several mechanisms of action that will be therapeutically useful in PTCL including reduction in survival and perturbation of trafficking.<\/jats:p>","DOI":"10.1038\/s41598-018-32634-5","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T14:49:46Z","timestamp":1537195786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma"],"prefix":"10.1038","volume":"8","author":[{"given":"Sami","family":"Mamand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Allchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Ahearne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-0370","authenticated-orcid":false,"given":"Simon D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"32634_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose, J., Armitage, J. & Weisenburger, D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of Clinical Oncology 26, 4124\u20134130 (2008).","journal-title":"Journal of Clinical Oncology"},{"key":"32634_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.34","volume":"4","author":"R Briski","year":"2014","unstructured":"Briski, R. et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J 4, e214 (2014).","journal-title":"Blood Cancer J"},{"key":"32634_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.14473","volume":"176","author":"N Schmitz","year":"2017","unstructured":"Schmitz, N. & de Leval, L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol 176, 851\u2013866 (2017).","journal-title":"Br J Haematol"},{"key":"32634_CR4","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz, N. et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116, 3418\u20133425 (2010).","journal-title":"Blood"},{"key":"32634_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier, B., Pro, B. & Prince, M. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. J Clin Oncol 30, 631\u2013636 (2012).","journal-title":"J Clin Oncol"},{"key":"32634_CR6","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor, O. A. et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29, 1182\u20131189 (2011).","journal-title":"J Clin Oncol"},{"key":"32634_CR7","doi-asserted-by":"crossref","first-page":"S8507","DOI":"10.1200\/jco.2013.31.15_suppl.8507","volume":"31","author":"OA O\u2019Connor","year":"2013","unstructured":"O\u2019Connor, O. A. et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): Results from the BELIEF trial. Journal of Clinical Oncology 31, S8507 (2013).","journal-title":"Journal of Clinical Oncology"},{"key":"32634_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.13222","volume":"168","author":"F Foss","year":"2015","unstructured":"Foss, F. et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 168, 811\u2013819 (2015).","journal-title":"Br J Haematol"},{"key":"32634_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer, P. et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. Journal of Clinical Oncology 27, 106\u2013113 (2009).","journal-title":"Journal of Clinical Oncology"},{"key":"32634_CR10","doi-asserted-by":"publisher","first-page":"e0161811","DOI":"10.1371\/journal.pone.0161811","volume":"11","author":"Y-T Yang","year":"2016","unstructured":"Yang, Y.-T. et al. Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review. Plos One 11, e0161811\u201314 (2016).","journal-title":"Plos One"},{"key":"32634_CR11","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal, S. et al. Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19, 958\u2013963 (2008).","journal-title":"Ann Oncol"},{"key":"32634_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1172\/JCI26833","volume":"117","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga, P. P. et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117, 823\u2013834 (2007).","journal-title":"J Clin Invest"},{"key":"32634_CR13","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L De Leval","year":"2007","unstructured":"De Leval, L. et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109, 4952\u20134963 (2007).","journal-title":"Blood"},{"key":"32634_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1084\/jem.20091738","volume":"207","author":"MA Linterman","year":"2010","unstructured":"Linterman, M. A. et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med 207, 353\u2013363 (2010).","journal-title":"J Exp Med"},{"key":"32634_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronn\u00e9","year":"2012","unstructured":"Couronn\u00e9, L., Bastard, C. & Bernard, O. A. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 366, 95\u201396 (2012).","journal-title":"N Engl J Med"},{"key":"32634_CR16","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier, F. et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 120, 1466\u20131469 (2012).","journal-title":"Blood"},{"key":"32634_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide, O. et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123, 1293\u20131296 (2014).","journal-title":"Blood"},{"key":"32634_CR18","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois, D. et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128, 1490\u20131502 (2016).","journal-title":"Blood"},{"key":"32634_CR19","doi-asserted-by":"publisher","first-page":"11194","DOI":"10.1073\/pnas.89.23.11194","volume":"89","author":"JD Siliciano","year":"1992","unstructured":"Siliciano, J. D., Morrow, T. A. & Desiderio, S. V. Itk, a T-cell-specific tyrosine kinase gene inducible by interleukin 2. Proc Natl Acad Sci USA 89, 11194\u201311198 (1992).","journal-title":"Proc Natl Acad Sci USA"},{"key":"32634_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/1074-7613(95)90065-9","volume":"3","author":"XC Liao","year":"1995","unstructured":"Liao, X. C. & Littman, D. R. Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity 3, 757\u2013769 (1995).","journal-title":"Immunity"},{"key":"32634_CR21","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.4049\/jimmunol.156.8.2716","volume":"156","author":"S Gibson","year":"1996","unstructured":"Gibson, S. et al. The EMT\/ITK\/TSK (EMT) tyrosine kinase is activated during TCR signaling: LCK is required for optimal activation of EMT. J Immunol 156, 2716\u20132722 (1996).","journal-title":"J Immunol"},{"key":"32634_CR22","doi-asserted-by":"publisher","first-page":"29816","DOI":"10.1074\/jbc.M312848200","volume":"279","author":"AM Fischer","year":"2004","unstructured":"Fischer, A. M., Mercer, J. C., Iyer, A., Ragin, M. J. & August, A. Regulation of CXC chemokine receptor 4-mediated migration by the Tec family tyrosine kinase ITK. J Biol Chem 279, 29816\u201329820 (2004).","journal-title":"J Biol Chem"},{"key":"32634_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.cub.2004.04.011","volume":"14","author":"A Takesono","year":"2004","unstructured":"Takesono, A., Horai, R., Mandai, M., Dombroski, D. & Schwartzberg, P. L. Requirement for Tec kinases in chemokine-induced migration and activation of Cdc42 and Rac. Curr Biol 14, 917\u2013922 (2004).","journal-title":"Curr Biol"},{"key":"32634_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1074-7613(00)80115-6","volume":"11","author":"DJ Fowell","year":"1999","unstructured":"Fowell, D. J. et al. Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. Immunity 11, 399\u2013409 (1999).","journal-title":"Immunity"},{"key":"32634_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nri1591","volume":"5","author":"PL Schwartzberg","year":"2005","unstructured":"Schwartzberg, P. L., Finkelstein, L. D. & Readinger, J. A. TEC-family kinases: regulators of T-helper-cell differentiation. Nat Rev Immunol 5, 284\u2013295 (2005).","journal-title":"Nat Rev Immunol"},{"key":"32634_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1084\/jem.20131459","volume":"211","author":"J Gomez-Rodriguez","year":"2014","unstructured":"Gomez-Rodriguez, J. et al. Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. Journal of Experimental Medicine 211, 529\u2013543 (2014).","journal-title":"Journal of Experimental Medicine"},{"key":"32634_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms10857","volume":"7","author":"J Gomez-Rodriguez","year":"2016","unstructured":"Gomez-Rodriguez, J. et al. Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4. Nature Communications 7, 1\u201315 (2016).","journal-title":"Nature Communications"},{"key":"32634_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15871","volume":"8","author":"W Huang","year":"2017","unstructured":"Huang, W., Solouki, S., Koylass, N., Zheng, S.-G. & August, A. ITK signalling via the Ras\/IRF4 pathway regulates the development and function of Tr1 cells. Nature Communications 8, 15871 (2017).","journal-title":"Nature Communications"},{"key":"32634_CR29","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1097\/PAS.0000000000000309","volume":"38","author":"C Agostinelli","year":"2014","unstructured":"Agostinelli, C. et al. Intracellular TCR-signaling pathway: novel markers for lymphoma diagnosis and potential therapeutic targets. Am. J. Surg. Pathol. 38, 1349\u20131359 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"32634_CR30","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1097\/PAS.0b013e3182991415","volume":"37","author":"AD Attygalle","year":"2013","unstructured":"Attygalle, A. D., Feldman, A. L. & Dogan, A. ITK\/SYK translocation in angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 37, 1456\u20131457 (2013).","journal-title":"Am. J. Surg. Pathol."},{"key":"32634_CR31","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"32634_CR32","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1084\/jem.20092042","volume":"207","author":"K Pechloff","year":"2010","unstructured":"Pechloff, K. et al. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. Journal of Experimental Medicine 207, 1031\u20131044 (2010).","journal-title":"Journal of Experimental Medicine"},{"key":"32634_CR33","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky, J. A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122, 2539\u20132549 (2013).","journal-title":"Blood"},{"key":"32634_CR34","first-page":"1","volume":"2","author":"AJJJCBJAD Yiming Zhong","year":"2014","unstructured":"Zhong, Y. et al. Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases. Postdoc. J 2, 1\u201311 (2014).","journal-title":"Postdoc. J"},{"key":"32634_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nri1330","volume":"4","author":"RT Abraham","year":"2004","unstructured":"Abraham, R. T. & Weiss, A. Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol 4, 301\u2013308 (2004).","journal-title":"Nat Rev Immunol"},{"key":"32634_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1034\/j.1600-065X.2003.00029.x","volume":"191","author":"JA Lucas","year":"2003","unstructured":"Lucas, J. A., Miller, A. T., Atherly, L. O. & Berg, L. J. The role of Tec family kinases in T cell development and function. Immunol Rev 191, 119\u2013138 (2003).","journal-title":"Immunol Rev"},{"key":"32634_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.it.2013.01.001","volume":"34","author":"JL Cannons","year":"2013","unstructured":"Cannons, J. L., Lu, K. T. & Schwartzberg, P. L. T follicular helper cell diversity and plasticity. Trends in Immunology 34, 200\u2013207 (2013).","journal-title":"Trends in Immunology"},{"key":"32634_CR38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.it.2016.06.001","volume":"37","author":"Y Tian","year":"2016","unstructured":"Tian, Y. & Zajac, A. J. IL-21 and T Cell Differentiation: Consider the Context. Trends in Immunology 37, 557\u2013568 (2016).","journal-title":"Trends in Immunology"},{"key":"32634_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1084\/jem.20091777","volume":"207","author":"D Zotos","year":"2010","unstructured":"Zotos, D. et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med 207, 365\u2013378 (2010).","journal-title":"J Exp Med"},{"key":"32634_CR40","doi-asserted-by":"publisher","first-page":"10568","DOI":"10.1074\/jbc.L115.644641","volume":"290","author":"S Dondorf","year":"2015","unstructured":"Dondorf, S., Schrader, A. & Herling, M. Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL). Journal of Biological Chemistry 290, 10568\u201310569 (2015).","journal-title":"Journal of Biological Chemistry"},{"key":"32634_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1600-065X.2008.00757.x","volume":"228","author":"JA Readinger","year":"2009","unstructured":"Readinger, J. A., Mueller, K. L., Venegas, A. M., Horai, R. & Schwartzberg, P. L. Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk\/Txk. Immunol Rev 228, 93\u2013114 (2009).","journal-title":"Immunol Rev"},{"key":"32634_CR42","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370, 997\u20131007 (2014).","journal-title":"N Engl J Med"},{"key":"32634_CR43","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","volume":"17","author":"IE Krop","year":"2016","unstructured":"Krop, I. E. et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 17, 811\u2013821 (2016).","journal-title":"Lancet Oncol"},{"key":"32634_CR44","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"32634_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","volume":"30","author":"JG Cyster","year":"2012","unstructured":"Cyster, J. G. & Schwab, S. R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30, 69\u201394 (2012).","journal-title":"Annu Rev Immunol"},{"key":"32634_CR46","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1517\/14712598.8.11.1797","volume":"8","author":"GL Uy","year":"2008","unstructured":"Uy, G. L., Rettig, M. P. & Cashen, A. F. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther 8, 1797\u20131804 (2008).","journal-title":"Expert Opin Biol Ther"},{"key":"32634_CR47","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1073\/pnas.1311846111","volume":"111","author":"LA Mathews Griner","year":"2014","unstructured":"Mathews Griner, L. A. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 111, 2349\u20132354 (2014).","journal-title":"Proc Natl Acad Sci USA"},{"key":"32634_CR48","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.4049\/jimmunol.1000202","volume":"184","author":"J Rolf","year":"2010","unstructured":"Rolf, J., Fairfax, K. & Turner, M. Signaling pathways in T follicular helper cells. The Journal of Immunology 184, 6563\u20136568 (2010).","journal-title":"The Journal of Immunology"},{"issue":"26","key":"32634_CR49","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"Suzanne L. Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med, https:\/\/doi.org\/10.1056\/NEJMoa1200690 (2012).","journal-title":"New England Journal of Medicine"},{"key":"32634_CR50","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin, A. M. et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology 34, 2698\u20132704 (2016).","journal-title":"Journal of Clinical Oncology"},{"key":"32634_CR51","doi-asserted-by":"publisher","first-page":"e000146","DOI":"10.1136\/lupus-2016-000146","volume":"3","author":"BA Sullivan","year":"2016","unstructured":"Sullivan, B. A. et al. Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. Lupus Sci Med 3, e000146 (2016).","journal-title":"Lupus Sci Med"},{"key":"32634_CR52","first-page":"1154","volume":"118","author":"SJ Jarmin","year":"2008","unstructured":"Jarmin, S. J. et al. T cell receptor-induced phosphoinositide-3-kinase p110delta activity is required for T cell localization to antigenic tissue in mice. J Clin Invest 118, 1154\u20131164 (2008).","journal-title":"J Clin Invest"},{"key":"32634_CR53","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.4049\/jimmunol.1001730","volume":"185","author":"J Rolf","year":"2010","unstructured":"Rolf, J. et al. Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. J Immunol 185, 4042\u20134052 (2010).","journal-title":"J Immunol"},{"key":"32634_CR54","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn, I. W. et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123, 3406\u20133413 (2014).","journal-title":"Blood"},{"key":"32634_CR55","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown, J. R. et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood 123, 3390\u20133397 (2014).","journal-title":"Blood"},{"key":"32634_CR56","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","volume":"114","author":"JA Burger","year":"2009","unstructured":"Burger, J. A., Ghia, P., Rosenwald, A. & Caligaris-Cappio, F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114, 3367\u20133375 (2009).","journal-title":"Blood"},{"key":"32634_CR57","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/leu.2011.301","volume":"26","author":"P Am\u00e9-Thomas","year":"2012","unstructured":"Am\u00e9-Thomas, P. et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26, 1053\u20131063 (2012).","journal-title":"Leukemia"},{"key":"32634_CR58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcancer.2013.11.004","volume":"24","author":"P Gaulard","year":"2014","unstructured":"Gaulard, P. & de Leval, L. The microenvironment in T-cell lymphomas: Emerging themes. Semin Cancer Biol 24, 49\u201360 (2014).","journal-title":"Semin Cancer Biol"},{"key":"32634_CR59","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","volume":"29","author":"S Crotty","year":"2010","unstructured":"Crotty, S. Follicular Helper CD4 T Cells (TFH). Annu Rev Immunol 29, 621\u2013663 (2010).","journal-title":"Annu Rev Immunol"},{"key":"32634_CR60","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/cncr.22510","volume":"109","author":"S Konoplev","year":"2007","unstructured":"Konoplev, S. et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 109, 1152\u20131156 (2007).","journal-title":"Cancer"},{"key":"32634_CR61","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1182\/blood-2006-05-024844","volume":"109","author":"AC Spoo","year":"2007","unstructured":"Spoo, A. C., L\u00fcbbert, M., Wierda, W. G. & Burger, J. A. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109, 786\u2013791 (2007).","journal-title":"Blood"},{"key":"32634_CR62","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-04-1887","volume":"11","author":"S Scala","year":"2005","unstructured":"Scala, S. et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11, 1835\u20131841 (2005).","journal-title":"Clin Cancer Res"},{"key":"32634_CR63","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","volume":"113","author":"Z Zeng","year":"2009","unstructured":"Zeng, Z. et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215\u20136224 (2009).","journal-title":"Blood"},{"key":"32634_CR64","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","volume":"113","author":"AK Azab","year":"2009","unstructured":"Azab, A. K. et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113, 4341\u20134351 (2009).","journal-title":"Blood"},{"key":"32634_CR65","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood-2011-04-347518","volume":"119","author":"K O\u2019Callaghan","year":"2012","unstructured":"O\u2019Callaghan, K. et al. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 119, 1717\u20131725 (2012).","journal-title":"Blood"},{"key":"32634_CR66","unstructured":"Witzig, T. E. et al. The CXCL12\/CXCR4 pathway as a potential target of Tipifarnib: preliminary results from an open-label phase II study in relapsed or refractory peripheral T-cell lymphoma. Blood ASH Abstract 2788 (2017)."},{"key":"32634_CR67","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","volume":"40","author":"B Coiffier","year":"2014","unstructured":"Coiffier, B. et al. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat. Rev. 40, 1080\u20131088 (2014).","journal-title":"Cancer Treat. Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32634-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32634-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32634-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:11:46Z","timestamp":1693890706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32634-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["32634"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-32634-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14216"}}